Kalaris Therapeutics, Inc. (KLRS)
CIK 1754068 · all EDGAR filings →
Same rating bands the category standard uses, but free, with the formula on the chip and the gaps in the data said out loud.
Shares outstanding over time
Latest: 23.8M shares as of Aug 4, 2026 (10-Q). Share count fell from 115.5M to 5.0M between Nov 5, 2024 and Feb 28, 2025, a pattern consistent with a reverse split (roughly 1-for-23); simultaneous issuance can skew the raw ratio, so confirm in the filings. The red bar marks the cliff.
Cash runway
Self-funding
generates cash
Full breakdown: cash runway tool · source filing →
Warrants
| Tranche | Warrants | Exercise price | Term | Notes |
|---|---|---|---|---|
| Pre-Funded Warrants | not tagged | $0.0001 | — | — |
Tranches exactly as the company dimensioned them in its 10-Q filed Aug 11, 2026 →. Groupings can overlap (a “Series E and F” row is not additive with a “Series E” row), so do not sum this column. A tranche the filer did not tag is absent here, not absent from the cap table. DOWN-ROUND = the filer tagged price-protection accounting scoped to that tranche.
No warrant figures tagged in this filer’s XBRL facts. That means the company has not reported them in structured form; it does not prove no warrants exist. The exhibits are the ground truth.
Convertible notes
| Note | Principal | Carrying | Conv. price | Rate | If converted |
|---|---|---|---|---|---|
| Convertible Promissory Note | $10.0M | — | $6.2 | 10% | ~1.6M sh |
| Twenty Twenty Four Bridge Notes | $10.0M | — | $6.2 | 8% | ~1.6M sh |
| Twenty Twenty Five Bridge Notes | $3.8M | — | $4.7851 | — | ~783,683 sh |
| January Twenty Twenty Five Allo Vir Convertible Promissory Note | $3.8M | — | not tagged | — | — |
If every note above converted at its tagged price: ~4.0M new shares on 23.8M currently outstanding. An estimate from principal ÷ conversion price, with inputs carrying different as-of dates; make-whole adjustments, capped calls and partial repurchases are not modeled.
Notes exactly as the company dimensioned them in its 10-Q filed Aug 11, 2026 →. Principal is face amount as tagged, not what remains after repurchases unless the filer updated the tag. A note the filer did not dimension is absent here, not absent from the balance sheet; the exhibits stay the ground truth.
Fully diluted build-up
Shares outstanding plus every potential-share instrument the filer tagged in XBRL, each at its own as-of date. An estimate assembled from filed figures, not a filing figure itself.
| Shares outstanding | 23.8M | Aug 4, 2026 |
| + Convertible Promissory Note (if fully converted) | 1.6M | Jun 30, 2026 |
| + Twenty Twenty Four Bridge Notes (if fully converted) | 1.6M | Jun 30, 2026 |
| + Twenty Twenty Five Bridge Notes (if fully converted) | 783,683 | Jun 30, 2026 |
| Fully diluted estimate | 27.8M | +16.8% vs O/S |
Still excluded, because the filer does not tag them in countable form: employee options and RSUs, any instrument living only in exhibit prose, and instruments above missing a share count. Inputs carry different as-of dates, shown per row. Each figure traces to the tranche and note tables above and their cited filings.
Registrations and offerings
Registered offering capacity on live registrations: $377.3Mfrom the structured fee exhibits; registered is not remaining, takedowns are not subtracted
Last 12 months: 1 executed · 2 registered.
Full history and shelf status: offering checker · S-3 shelf checker
Source: SEC EDGAR XBRL company facts and filing metadata, fetched live and cached briefly. Share counts are cover-page figures with their form named. Warrant tranches and convertible notes come from the dimensioned facts in the latest 10-Q/10-K instance document, exactly as the company tagged them; untagged tranches and notes are absent, not disproven. Nothing on this page is manually verified and nothing is behind a login: what free data supports is shown, what it cannot support is stated. Not investment advice.
Keep going: float checker · offering calendar · short-squeeze screener · full KLRS workspace